Recently released market study: Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Fast Market Research recommends "Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2012" from Global Markets Direct, now available
By: Fast Market Research, Inc.
 
 
Spread the Word
Listed Under

Tags:
Progenics
Pharmaceuticals
Pipeline

Industry:
Medical

Location:
Massachusetts - US

Nov. 17, 2012 - PRLog -- Global Market Direct's pharmaceuticals report, "Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2012" provides data on the Progenics Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Progenics Pharmaceuticals, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Progenics Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Progenics Pharmaceuticals, Inc. - Brief Progenics Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Progenics Pharmaceuticals, Inc. human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Progenics Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Progenics Pharmaceuticals, Inc.'s pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/468588_progenics_pharmaceutica...
------------------------------------------------------------

Reasons to buy

* Evaluate Progenics Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Progenics Pharmaceuticals, Inc..
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Progenics Pharmaceuticals, Inc. Snapshot
Progenics Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Progenics Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
Progenics Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Progenics Pharmaceuticals, Inc. - Pipeline Products Glance
Progenics Pharmaceuticals, Inc. - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Progenics Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Progenics Pharmaceuticals, Inc. - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Progenics Pharmaceuticals, Inc. - Drug Profiles
methylnaltrexone bromide
Product Description
Mechanism of Action
R&D Progress
Multiplex PI3K Inhibitors
Product Description
Mechanism of Action
R&D Progress
PSMA ADC
Product Description
Mechanism of Action
R&D Progress
Relistor
Product Description
Mechanism of Action
R&D Progress
Progenics Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
Progenics Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action
Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates
Progenics Pharmaceuticals, Inc. - Dormant Projects
Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Clostridium Difficile Antibodies
HCV-Entry Inhibitor
PRO-140
PRO-206
PSMA VRP Vaccine
Progenics Pharmaceuticals, Inc. - Company Statement
Progenics Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Progenics Pharmaceuticals, Inc., Recent Developments
Progenics Pharmaceuticals, Inc.- Press Release
Jul 27, 2012: Salix Pharma And Progenics Pharma Receive Complete Response Letter From FDA For Relistor sNDA
Apr 25, 2012: Salix And Progenics Announce FDA Extension Of Relistor sNDA Goal Date
Oct 14, 2009: Progenics Regains Worldwide Rights to Relistor Franchise
Aug 04, 2009: New Delivery System for Relistor in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Jun 08, 2009: Progenics Provides Update On Hepatitis C Program
Feb 10, 2009: Progenics Selects Subcutaneous Form Of PRO 140, A Novel HIV Antibody Therapy, For Further Development
Financial Deals Landscape
Progenics Pharmaceuticals, Inc., Deals Summary
Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Progenics Pharma Extends Its Commercialization Agreement With Wyeth Pharma
Progenics Pharma Enters Into Agreement With Seattle Genetics
Licensing Agreements
Salix Pharma Enters Into Licensing Agreement With Progenics Pharma For Relistor
Ono Pharma Enters Into Licensing Agreement With Progenics Pharma
Equity Offering
Progenics Pharma Files Registration Statement For $100 Million
Progenics Pharma Completes Public Offering Of $60 Million
Asset Transactions

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4685...

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.
End
Email:***@fastmr.com Email Verified
Phone:1.800.844.8156
Zip:01267
Tags:Progenics, Pharmaceuticals, Pipeline
Industry:Medical
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share